Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?

Lakatos, Peter Laszlo; de Boer, N. K. H.
April 2009
World Journal of Gastroenterology;5/21/2009, Vol. 15 Issue 15, p1799
Academic Journal
5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine. However, poor adherence due to frequent daily dosing and a large number of tablets has been shown to be an important barrier to successful management of patients with UC. Recently, new, once-daily formulations of mesalazine, including the unique multi-matrix delivery system and mesalazine granules, were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC, with a good safety profile comparable to that of other oral mesalazine formulations. In addition, they offer the advantage of a low pill burden and might contribute to increased long-term compliance and treatment success in clinical practice. This editorial summarizes the available literature on the short- and medium-term efficacy and safety of the new once-daily mesalazine formulations.


Related Articles

  • 5-ASA in ulcerative colitis: Improving treatment compliance. Prantera, Cosimo; Rizzi, Marina; Danese, Silvio // World Journal of Gastroenterology;9/21/2009, Vol. 15 Issue 35, p4353 

    5-aminosalicylic acid (5-ASA) compounds are a highly effective treatment for ulcerative colitis (UC). While UC patient compliance in clinical studies is over 90%, only 40% of patients in every day life take their prescribed therapy. Adherence to medication has been emphasized recently by a...

  • Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Hiwatashi, Nobuo; Suzuki, Yasuo; Mitsuyama, Keiichi; Munakata, Akihiro; Hibi, Toshifumi // Journal of Gastroenterology;Jan2011, Vol. 46 Issue 1, p46 

    Background and aims: Oral mesalazine formulations are effective in the treatment of active ulcerative colitis (UC). It is not clear what induction dose of mesalazine is optimal for treating patients with active UC. We aimed to evaluate the efficacy and safety of 4 versus 2.25 g/day for selected...

  • A Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Mesalamine Suppositories 1 g at Bedtime and 500 mg Twice Daily in Patients with Active Mild-to-Moderate Ulcerative Proctitis. Lamet, Mark // Digestive Diseases & Sciences;Feb2011, Vol. 56 Issue 2, p513 

    Background: Ulcerative proctitis (UP) is a prevalent condition associated with increased morbidity and mortality. Topical mesalamine (5-aminosalicylic acid [5-ASA]) inhibits inflammatory processes in UP. Methods: We evaluated effects of mesalamine 1-g suppository administered QHS compared with...

  • Olsalazine in active ulcerative colitis. Selby, W.S.; Barr, G.D.; Ireland, A.; Mason, C.H.; Jewell, D.P. // British Medical Journal (Clinical Research Edition);11/16/1985, Vol. 291 Issue 6506, p1373 

    Examines the effectiveness of olsalazine in treating active ulcerative colitis. Features of olsalazine; Rate of clinical improvements in patients after taking oral olsalazine; Role of olsalazine in maintaining remission.

  • Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Dew, M.J.; Harries, A.D.; Evans, N.; Evans, B.K.; Rhodes, J. // British Medical Journal (Clinical Research Edition);7/2/1983, Vol. 287 Issue 6384, p23 

    Focuses on the efficacy of 5-amino salicylic acid treatment for ulcerative colitis. Similarity of the drug to sulphasalazine in maintaining ulcerative colitis remission; Manifestations of the disease during relapse; Efficacy of high doses of 5-amino salicylic acid and suphasalazine.

  • Infliximab to treat severe ulcerative colitis. Cury, Dídia Bisamra; Cury, Marcelo de Souza; Hemerly Elias, Geraldo Vinicius; Mizsputen, Sender Jankiel; Pravda, Jay // World Journal of Gastroenterology;4/14/2009, Vol. 15 Issue 14, p1771 

    A 48-year-old female with severe ulcerative colitis refractory to conventional therapy was referred to our facility for management. The patient showed extensive ulcerative colitis since the age of 20 years and had failed therapy with 5-aminosalicylic acid agents and azathioprine. The disease...

  • Asacol.  // Royal Society of Medicine: Medicines;2002, p88 

    The article presents information on Asacol, a proprietary, prescription-only preparation of the aminosalicylate mesalazine. It can be used to treat patients who suffer from ulcerative colitis but who are unable to tolerate the more commonly used sulfasalazine. It is available as tablets, a foam...

  • Similar remission results shown between once-daily 4g dose and twice-daily 2g doses of mesalazine (Pentasa(r)) in active ulcerative colitis.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p272 

    The article reports on a study which aims to show noninferiority of once daily mesalazine (Pentasa) versus the standard twice-daily dosing for the induction of remission in active ulcerative colitis. It examines patients with active mild-to-moderate ulcerative colitis treated with 4g mesalazine...

  • Particle Size Determination in Pharmaceutical Applications.  // LabAsia;2011, Vol. 18 Issue 1, p22 

    The article focuses on the importance of the particle size of dosage forms in the efficacy of the drug.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics